LogicBio Therapeutics, Inc. (LOGC): Price and Financial Metrics


LogicBio Therapeutics, Inc. (LOGC): $1.55

-0.15 (-8.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

LOGC POWR Grades


  • Sentiment is the dimension where LOGC ranks best; there it ranks ahead of 65.76% of US stocks.
  • LOGC's strongest trending metric is Sentiment; it's been moving up over the last 77 days.
  • LOGC ranks lowest in Momentum; there it ranks in the 18th percentile.

LOGC Stock Summary

  • LOGC's went public 3.26 years ago, making it older than just 9.3% of listed US stocks we're tracking.
  • LOGC's price/sales ratio is 14.78; that's higher than the P/S ratio of 90.14% of US stocks.
  • LogicBio Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -85.62%, greater than the shareholder yield of only 4.64% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to LogicBio Therapeutics Inc, a group of peers worth examining would be AGLE, RGLS, TMDI, GSIT, and CRIS.
  • Visit LOGC's SEC page to see the company's official filings. To visit the company's web site, go to www.logicbio.com.

LOGC Valuation Summary

  • In comparison to the median Healthcare stock, LOGC's price/sales ratio is 1373.68% higher, now standing at 56.
  • LOGC's EV/EBIT ratio has moved up 25.1 over the prior 35 months.
  • LOGC's EV/EBIT ratio has moved up 25.1 over the prior 35 months.

Below are key valuation metrics over time for LOGC.

Stock Date P/S P/B P/E EV/EBIT
LOGC 2021-08-31 56.0 3.4 -4.3 -2.9
LOGC 2021-08-30 54.9 3.3 -4.2 -2.8
LOGC 2021-08-27 55.3 3.4 -4.2 -2.8
LOGC 2021-08-26 52.5 3.2 -4.0 -2.6
LOGC 2021-08-25 52.5 3.2 -4.0 -2.6
LOGC 2021-08-24 51.6 3.1 -3.9 -2.5

LOGC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LOGC has a Quality Grade of C, ranking ahead of 45.61% of graded US stocks.
  • LOGC's asset turnover comes in at 0.04 -- ranking 336th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows LOGC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.040 1 -2.039
2021-03-31 0.047 1 -1.619
2020-12-31 0.063 1 -1.754
2020-09-30 0.060 1 -1.813
2020-06-30 0.036 1 -1.663
2020-03-31 0.017 1 -1.504

LOGC Price Target

For more insight on analysts targets of LOGC, see our LOGC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $18.80 Average Broker Recommendation 1.33 (Strong Buy)

LOGC Stock Price Chart Interactive Chart >

Price chart for LOGC

LOGC Price/Volume Stats

Current price $1.55 52-week high $9.75
Prev. close $1.70 52-week low $1.45
Day low $1.45 Volume 117,800
Day high $1.70 Avg. volume 66,157
50-day MA $2.63 Dividend yield N/A
200-day MA $4.04 Market Cap 51.08M

LogicBio Therapeutics, Inc. (LOGC) Company Bio


LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.


LOGC Latest News Stream


Event/Time News Detail
Loading, please wait...

LOGC Latest Social Stream


Loading social stream, please wait...

View Full LOGC Social Stream

Latest LOGC News From Around the Web

Below are the latest news stories about LogicBio Therapeutics Inc that investors may wish to consider to help them evaluate LOGC as an investment opportunity.

LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Fred Chereau, will participate in a fireside chat at the virtual H.C. Wainwright Bioconnect Conference being held January 10-13, 2022. The pre-recorded presentation will be available for on-demand viewing beginning at 7:00 a.m. ET on Monday, January 10, 2022.

Yahoo | January 4, 2022

LogicBio Therapeutics (NASDAQ:LOGC) Price Target Lowered to $16.00 at Chardan Capital

LogicBio Therapeutics (NASDAQ:LOGC) had its target price lowered by Chardan Capital from $20.00 to $16.00 in a research note issued to investors on Thursday morning, PriceTargets.com reports. The brokerage currently has a buy rating on the stock. LOGC has been the topic of several other reports. Zacks Investment Research cut LogicBio Therapeutics from a hold []

Dakota Financial News | December 24, 2021

H.C. Wainwright Keeps a Buy Rating on Logicbio Therapeutics (LOGC)

H.C. Wainwright analyst Edwin Zhang maintained a Buy rating on Logicbio Therapeutics (LOGC – Research Report) today and set a price target of $15.00. The company's shares closed last Wednesday at $2.33. According to TipRanks.com, Zhang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.9% and a 11.1% success rate. Zhang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Calliditas Therapeutics, and Reneo Pharmaceuticals. Currently, the analyst consensus on Logicbio Therapeutics is a Strong Buy with an average price target of $13.00. See the top stocks recommended by analysts >> The company has a one-year high of $9.

Catie Powers on TipRanks | December 22, 2021

LogicBio Therapeutics Provides Business Updates

LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided updates around its SUNRISE Phase 1/2 clinical trial and development pipeline, and announced the appointment of Susan R. Kahn to its Board of Directors.

Yahoo | December 22, 2021

State Street Corp Lowers Stake in LogicBio Therapeutics, Inc. (NASDAQ:LOGC)

State Street Corp reduced its position in shares of LogicBio Therapeutics, Inc. (NASDAQ:LOGC) by 89.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,807 shares of the companys stock after selling 208,732 shares during the quarter. State Street Corp []

Transcript Daily | December 12, 2021

Read More 'LOGC' Stories Here

LOGC Price Returns

1-mo N/A
3-mo -59.42%
6-mo -63.36%
1-year -82.91%
3-year -81.55%
5-year N/A
YTD -32.90%
2021 -69.72%
2020 5.97%
2019 -30.77%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8043 seconds.